Cytosorbents Corporation · NASDAQ:CTSO
Cytosorbents — Investor Presentation (October 2025)
28 slides from Cytosorbents's investor presentation, October 2025
Slide 1: Investor Presentation October 2025
NASDAQ: CTSO Investor Presentation October 2025 1 |
Slide 2: Safe Harbor Statement
Safe Harbor Statement Statements in this presentation regarding CytoSorbents Corporation and its operating subsidiaries CytoSorbents Medical, Inc and CytoSorbents Europe GmbH that are not historical facts are forward-looking statements and are subject to risks and uncertainties that could cause actu
Slide 3: CytoSorbents (Nasdaq: CTSO) at a Glance
CytoSorbents (Nasdaq: CTSO) at a Glance • Platform blood purification technology for removing toxins and harmful substances from a patient’s blood • High margin “razorblade” disposables that are “plug and play” into existing hospital blood pumps • Two main products leverage the underlying polymer te
Slide 4: The Power of the Bead
The Power of the Bead Hemocompatible, highly porous polymer bead platform technology that act like tiny sponges to remove harmful substances from blood by pore capture, adsorption, and concentration • Excellent removal of a broad range of substances from whole blood and plasma • Solid state porous p
Slide 5: Expanding the Dimension of Blood Purification
Expanding the Dimension of Blood Purification CytoSorb is a powerful blood purification technology that removes a broad range of harmful substances that dialysis does not CytoSorb works like the liver Dialysis works like the kidney Large Molecules and Fat soluble substances Small Molecules and Water
Slide 6: CytoSorb: Our Core Business
CytoSorb Our Core Business 6 |
Slide 7: CytoSorb Controls Massive Inflammation - the Heart of Critical Illness
CytoSorb Controls Massive Inflammation - the Heart of Critical Illness • Acute inflammation is the body’s mechanism to fight injury and infection • However, severe inflammation, driven by cytokine storm, can cause a chain reaction of problems that can end in organ failure and death CAPILLARY IMMUNE
Slide 8: Targets Deadly Conditions That Afflict Millions of People
Targets Deadly Conditions That Afflict Millions of People Critical Care Cardiothoracic Surgery Removes the “fuel to the fire” of massive Reduces inflammation and blood thinners, uncontrolled inflammation that is often targeting reduction in complications of cardiac associated with organ failure and
Slide 9: This is Why CytoSorb Continues To Grow in ICU applications
This is Why CytoSorb Continues To Grow in ICU applications Sepsis, Septic Shock, Liver Cytokine storm/ Other Shock Cytokine release Pancreatitis failure syndrome Infectious diseases Post-surgical Neuroinflammation (flu, COVID-19, other) Burn injury complications Organ transplant Acute Respiratory Hi
Slide 10: Sepsis and Septic Shock are Deadly
Sepsis and Septic Shock are Deadly • Sepsis is a complex life-threatening condition where the inflammatory response to a serious infection can spiral out of control, fueled by the excessive production of cytokines (cytokine storm), bacterial toxins, and other inflammatory agents • Unchecked, massive
Slide 11: CytoSorbents is Leading a New Era in Sepsis Treatment
CytoSorbents is Leading a New Era in Sepsis Treatment For more than a decade, CytoSorbents has collaborated with clinicians and scientists around the world to advance the treatment of sepsis and septic shock by complementing traditional antibiotics with the broad-spectrum capability of CytoSorb Cyto
Slide 12: CytoSorb Enables Multi-Faceted Attack on Septic Shock
CytoSorb Enables Multi-Faceted Attack on Septic Shock A wealth of published, peer-reviewed studies support the broad mechanisms of action of CytoSorb that enable a comprehensive and multi-faceted attack on septic shock – from beginning to end CytoSorb helps to achieve the Core Treatment Goals in Sep
Slide 13: The Key to Success: Right Patient, Right Timing, Right Dosing
The Key to Success: Right Patient, Right Timing, Right Dosing Right Patient Just like antibiotics, CytoSorb works most effectively when: Highest • Treat Early Chance for • Treat Intensively Good Cinical • Compete the Full Course of Treatment Outcome Right Right Timing Dose 13 |
Slide 14: 2025: COSMOS Registry Highlights Treatment Strategy Success
2025: COSMOS Registry Highlights Treatment Strategy Success COSMOS registry, patient characteristics CAPILLARY LUNG • Data from 150 patients analyzed SHOCK LEAK FUNCTION • Critical care indications: Septic shock (57.6%) Cardiogenic shock (12.9%) Rhabdomyolysis (10.6%) Acute/acute-on-chronic liver fa
Slide 15: 2025: Early & Intensive Treatment with More Blood Treated Works Best
2025: Early & Intensive Treatment with More Blood Treated Works Best • Large, retrospective single center study • 175 patients with septic shock treated with CytoSorb • Evaluated the impact of early versus late, and low versus high intensity treatment with CytoSorb on mortality compared to predicted
Slide 16: CytoSorb Improves Survival in Septic Shock Meta-Analysis
CytoSorb Improves Survival in Septic Shock Meta-Analysis • Meta-analysis of 744 septic shock patients from 1 RCT and 8 observational studies from 2019-2024, of which 449 patients were treated with CytoSorb • CytoSorb reduced in-hospital mortality (OR 0.64, p=0.04) • 28-30-day mortality was also halv
Slide 17: Turning the Tide of Sepsis and Septic Shock: Real World Insights with CytoSorb
Turning the Tide of Sepsis and Septic Shock: Real World Insights with CytoSorb September 10, 2025 Link to webinar replay: https://cyto.news/webinar-sepsis/sep10 17 |
Slide 18: The Opportunity of DrugSorb-ATR
The Opportunity of 18 | * The DrugSorb-ATR system is an investigational device that is not yet cleared/approved by FDA, Health Canada, or by any other Global Regulatory Agency and is not commercially available for sale
Slide 19: Blood Thinners Can Cause Serious Perioperative Bleeding
Blood Thinners Can Cause Serious Perioperative Bleeding DrugSorb-ATR can help • Millions of people are on blood thinners to reduce their risk of heart attack and stroke • Acute heart attack patients commonly receive “super-aspirin” blood thinners like Brilinta® to improve clinical outcomes • But Bri
Slide 20: Brilinta and the Use Case for DrugSorb-ATR
® Brilinta and the Use Case for 5 - 10% will need open heart surgery The ultimate goal of DrugSorb-ATR is to allow patients to get the critical surgery they need without X X XX X delay, while reducing or preventing 20 | bleeding complications
Slide 21: Continued Real World Validation
Continued Real World Validation We continue to demonstrate and be recognized for the ability to address the critical global unmet need of reducing serious bleeding in CABG patients on Brilinta® • At EuroPCR (May 2025), Prof. Robert Storey presented a new comparative analysis of bleeding risk in 150
Slide 22: FDA and Health Canada Regulatory Update
FDA and Health Canada Regulatory Update • Submitted DrugSorb-ATR U.S. FDA De Novo and Health Canada Medical Device License applications for Brilinta® in CABG which included STAR-T RCT data and STAR registry real world evidence (RWE) in late-2024 • Interactive review with FDA resolved many issues, ho
Slide 23: Financial Performance
23 Financial Performance CytoSorbents.
Slide 24: Q2 2025 Revenue and Gross Margin
Q2 2025 Revenue and Gross Margin 2Q25 2Q24 YoY Change • Revenue led by 22% growth year-over-year and sequentially in Germany with continued strength in our other direct territories Revenue $9.6m $8.8m +9% • Distributor sales were among our best ever, second Constant currency only to a record Q2 2024
Slide 25: Annual Product Sales
Annual Product Sales CytoSorbents sells through Direct Sales in 9 countries and Distributors in 60+ others $45.0 Annual Product Sales $40.0 $39.5M $40.1M $6.3 $9.4 $36.1M $35.6M $35.0 $36.1 $35.6 $33.8 $31.1M* $30.0 $29.4M* $31.1 $30.1 $29.1 $ IN MILLONS $25.0 $22.8 $20.0 $20.3 $15.0 $13.4 $10.0 $8.
Slide 26: Strong Balance Sheet Driving Core Business toward Cash Flow Breakeven
Strong Balance Sheet Driving Core Business toward Cash Flow Breakeven as we exit 2025 • $11.7 million in cash, cash equivalents and restricted cash at June 30, 2025 • Includes $1.7 million received in April from Sale of NJ NOL and R&D credits We continue to prioritize initiatives to drive revenue gr
Slide 27: A Clear and Compelling Value Proposition
A Clear and Compelling Value Proposition CytoSorb is the basis of our established, international core business in critical care and cardiac surgery with $36M+ (ttm 6/30/25) in high margin product sales with expectations for growth due to: • Significant market opportunity, targeting major unmet medic
Slide 28: CytoSorbents Corporation
CytoSorbents Corporation NASDAQ: CTSO Company Contact: Dr. Phillip Chan pchan@cytosorbents.com www.cytosorbents.com 28